Gemina Laboratories Ltd. (TSE:GLAB) has released an update.
Gemina Laboratories Ltd. has enhanced its intellectual property portfolio by licensing a new biosensing technology from the University of British Columbia, which promises to advance point-of-care diagnostics with high-sensitivity and affordability. The novel biosensing architecture will contribute to the development of diagnostic tests, including a test kit targeting tuberculosis that aligns with the global health initiative to end TB by 2030. This strategic move aligns with Gemina’s ongoing efforts to broaden the application of its core technology platform in point-of-care diagnostics.
For further insights into TSE:GLAB stock, check out TipRanks’ Stock Analysis page.
